Back to search results

IV Ensure for Patients Receiving IV Antibiotics at Home

This study is looking at how well patients take their IV (intravenous) antibiotics at home after leaving the hospital, and if this affects whether they need to be readmitted. It uses a special device called IV Ensure to record when and for how long you take your IV medications. The goal is to see if better adherence (taking medicine as prescribed) can lead to fewer hospital readmissions. You may be able to join if you are an adult receiving IV antibiotics at home. The study will measure readmissions due to related infections up to 30 days after you finish your IV medication. The current recruitment status is unclear.

Study design
This study plans to enroll 90 participants. It is an interventional study, meaning participants will receive a specific intervention (the IV Ensure device).
What's involved
The study involves using the IV Ensure device to record and send data about your IV medication use at home.
Compensation
Not stated in the trial record.
Follow-up
You will be followed from enrollment until 30 days after you complete your prescribed IV medication to check for readmission due to subsequent related infection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06623318

IV Ensure in Patients Receiving OPAT

Recruiting
NAAges 18+InterventionalHealth services
IV Ensure
~90 participants
Updated 2024-10-02 on ClinicalTrials.gov
What's tested:Remote therapeutic monitoring device

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Readmission due to subsequent related infection following the initial encounter.
Measured over From enrollment to 30 days after completion of prescribed IV medication.

Conditions

Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates

Explore related trials

Infection

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Joseph Sassine, MD, FACP · PRINCIPAL_INVESTIGATOR · The University of Oklahoma Health Sciences Center

Who to contact

Mitchell T Berenson, MPH
[email protected]
214-924-6951
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients enrolled in OPAT (IV antibiotic therapy) discharged to the home setting will be included in the study.

Exclusion

Patients enrolled in OPAT (IV antibiotic therapy) discharged to nursing homes, SNF (Skilled Nursing Facility), and pediatric patients will be excluded from the study.

What this trial measures

  • Readmission due to subsequent related infection following the initial encounter.From enrollment to 30 days after completion of prescribed IV medication.

    This will be defined as a dichotomous outcome variable with Yes occurring when (a) a patients ID reoccurs in the OU Medicine EMR/EHR data pull within 30 days of their discharge with IV Ensure remote therapeutic monitoring device and (b) the patients readmissions reason matched the pre-specified list of ICD codes corresponding to secondary or downstream infections. If both of the above do not occur, the readmission variable will be set to No.